Harm van Tinteren

TL;DR: Cytoreduction followed by HIPEC improves survival in patients with peritoneal carcinomatosis of colorectal origin, however, patients with involvement of six or more regions of the abdominal cavity, or grossly incomplete cytoreduction, had still a grave prognosis.

TL;DR: Among patients with stage III epithelial ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in longer recurrence‐free survival and overall survival than surgery alone and did not result in higher rates of side effects.

TL;DR: It is shown that cytoreduction followed by HIPEC does significantly add survival time to patients affected by peritoneal carcinomatosis of colorectal origin and for a selected group, there is a possibility of long-term survival.

TL;DR: Addition of PET to conventional workup prevented unnecessary surgery in one out of five patients with suspected non-small-cell lung cancer, and the primary outcome measure was futile thoracotomy.

TL;DR: It is found that neoadjuvant ipilimumab + nivolumab expand more tumor-resident T cell clones than adjuvant application, and warrants future evaluation with modified dosing schedules to reduce treatment-related adverse events.